1995 update of the working group reports on chronic renal failure and renovascular hypertension national high blood pressure education program working group

Archives of Internal Medicine

Volumn 156, Issue 17, 1996, Pages 1938-1947

  Roccella, J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DISEASE ASSOCIATION; ENZYME INHIBITION; HUMAN; MASS SCREENING; MICROALBUMINURIA; NEPHROSCLEROSIS; PATIENT EDUCATION; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; SCREENING TEST;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, RENOVASCULAR; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; PREVALENCE; UNITED STATES;

EID: 10144220006     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.17.1938     Document Type: Review

References (98)

1. US Renal Data System. USROS 1994 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1994.
2. National High Blood Pressure Education Program. National High Blood Pressure Education Program working group report on hypertension and chronic renal failure. Arch Intern Med. 1991; 151:1280-1287.
3. Working Group on Renovascular Hypertension. Detection, evaluation, and treatment of renovascular hypertension. Arch Intern Med. 1987;147: 820-829.
4. Shulman NB, Ford CE, Hall DW, et al, for the Hypertension Detection and Follow-up Program. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension. 1989;13 (suppl l):80-93.
5. Walker GW, Neaton JD, Cutler JA, Neuwirth R, Cohen JD, for the MRFIT Research Group. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. JAMA. 1992;268: 3085-3091.
6. Brancati FL, Whelton PK, Whittle JC, Klag MJ. Epidemiologic analysis of existing data to investigate hypertensive renal disease: an example from the Maryland End-Stage Renal Disease Registry. Am J Kidney Dis. 1993;21(suppl 1):15-24.
7. Klag MJ, Whelton PK, Neaton JD, et al. Blood pressure and incidence of ESRD in men: a prospective study. Circulation. 1994;18:941.
8. Perneger TV, Nieto FJ, Whelton PK, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine: results from the 'Clue' study and the ARIC study. JAMA. 1993; 269:488-493.
9. Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med. 1990;150: 2073-2076.
10. Perry HM, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995;25:587-594.
11. Feldman HI, Klag MJ, Chiapella AP, Whelton PK. End-stage renal disease in US minority groups. Am J Kidney Dis. 1992;19:397-410.
12. Klag MJ, Whelton PK, Neaton JD, et al. Higher incidence of ESRD in African-American men in the MRFIT Screenee Cohort. J Am Soc Nephrol. 1994;5:334.
13. Rostand SG. US minority groups and end-stage renal disease: a disproportionate share. Am J Kidney Dis. 1992;19:411-413.
14. Perneger TV, Whelton PK, Klag MJ. Race and end-stage renal disease: socioeconomic status and access to health care as mediating factors. Arch Intern Med. 1995;155:1201-1208.
15. Ferguson R, Grim CE, Opgenorth TJ. A familial risk of chronic renal failure among blacks on dialysis? J Clin Epidemiol. 1988;41:1189-1196.
16. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis. 1993;21:387-393.
17. Whittle JC, Whelton PK, Seidler AJ, Klag MJ. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease? Arch Intern Med. 1991;151:1359-1364.
18. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ. The excess incidence of diabetic end-stage renal disease among blacks: a population-based study of potential explanatory factors. JAMA. 1992;268:3079-3084.
19. Perneger TV, Klag MJ, Whelton PK. Does low socioeconomic status (SES) explain racial differences in ESRD incidence? J Am Soc Nephrol. 1992;3:288.
20. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19:403-418.
21. Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med. 1989;320:966-970.
22. Christensen CK. Abnormal albumin and blood pressure rise in incipient diabetic nephropathy induced by exercise. Kidney Int. 1984;25:819-823.
23. Baldwin DS, Neugarten J. Blood pressure control and progression of renal insufficiency. In: Brenner BM, Stein JH, eds. Contemporary Issues in Nephrology. New York, NY: Churchill Livingstone Inc; 1986;14:81-110.
24. Bergström J, Alverstrand A, Bucht H, Guitierrez A. Stockholm clinical study on progression of chronic renal failure: an interim report. Kidney Int. 1989;27(suppl):110-114.
25. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989;35:670-674.
26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329: 1456-1462.
27. Klahr S, Levey AS, Beck GJ, et al, for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877-884.
28. Hunsicker LG, Adler S, Caggiula A, et al, for the MDRD Study Group. Relationship among baseline proteinuria (P), mean arterial blood pressure (MAP) during follow-up, and decline in glomerular filtration rate (GFR) in the Modification of Diet in Renal Disease Study (MDRD). J Am Soc Nephrol. 1993;4:254.
29. Berg R, Buckalew V, Pearce G, Porush J, Rauch S, Schulman G, for the MDRD Study Group. Differences between hypertensive and normotensive patients in the Modification of Diet in Renal Disease Study (MDRD) cohort. Presented at the Twelfth International Congress of Nephrology; June 13-18, 1993; Jerusalem, Israel. Abstract, page 594.
30. Parving H-H, Mogensen CE, Jensen HÆE, Evrin P-E. Increased urinary albumin-excretion rate in benign essential hypertension. Lancet. 1974;1: 1190-1192.
31. Pedersen EB, Mogensen CE. Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate, and renal plasma flow in patients with essential hypertension. Scand J Clin Lab Invest. 1976;36:231-237.
32. 2-microglobulin hyperexcretion in recent severe essential hypertension. J Hypertens. 1983;1:45-51.
33. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program working group report on hypertension and diabetes. Hypertension. 1994; 23:145-158.
34. Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis. 1995; 25:107-112.
35. Ruilope LM, Alcázar JM, Rodicio JM. Renal consequences of arterial hypertension. J Hypertens. 1992;10(suppl 7):85-90.
36. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993;153:154-183.
37. Hypertension Detection and Follow-up Program Cooperative Group. Therapeutic control of blood pressure in the Hypertension Detection and Follow-up Program. Prev Med. 1979;8:2-13.
38. Tierney WM, Harris LE, Copley JB, Luft FC. Effect of hypertension and type II diabetes on renal function in an urban population. Am J Hypertens. 1990;3:69-75.
39. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med. 1989;320:684-688.
40. Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet. 1995;345:749-751.
41. Mitch WE. Measuring the rate of progression of renal insufficiency. In: Brenner BM, Stein JH, eds. Contemporary Issues in Nephrology. New York, NY: Churchill Livingstone Inc; 1986;14:167-187.
42. Modification of Diet in Renal Disease Study Group. The Modification of Diet in Renal Disease Study: design, methods, and results from the feasibility study. Am J Kidney Dis. 1992;20:18-33.
43. Wight JP, Brown CB, EI Nahas AM. Effect of control of hypertension on progressive renal failure. Clin Nephrol. 1993;39:305-311.
44. Alvestrand A, Gutierrez A, Bucht H, Bergström J. Reduction of blood pressure retards the progression of chronic renal failure in man. Nephrol Dial Transplant. 1988;3:624-631.
45. Peterson JC, Burkhart J, Greene T, et al, for the MDRD Study Group. The effect of blood pressure control on progression of renal disease depends on level of proteinuria (P) at baseline evaluation. J Am Soc Nephrol. 1993;4:254.
46. Kusek JW, Agodoa L, Greene T, Jones C, for the MDRD Study Group. Comparison of decline of GFR in blacks vs nonblacks in the MDRD study. J Am Soc Nephrol. 1993;4:253.
47. Zucchelli P, Zuccalá A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452-458.
48. Bergström J, Alvestrand A, Bucht M, Gutierrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol. 1986;25:1-6.
49. Dillon JJ. The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am J Kidney Dis. 1993;22: 798-802.
50. Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis. 1993;22:164-173.
51. Parving HH, Smidt UM, Hommel E, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis. 1993;22:188-195.
52. Hebert LA, Bain RP, Verne D, et al, for the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int. 1994;46:1688-1693.
53. Bauer JH, Reams GP, Lal SM. Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med. 1987;147:1397-1400.
54. Pettinger WA, Lee HC, Reisch J, Mitchell HC. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension. 1989;13:766-772.
55. Klahr S, Beck G, Breyer J, et al, for the MDRD Study Group. Dietary protein restriction and reduced blood pressure goal in adults with polycystic kidney disease (APKD). J Am Soc Nephrol. 1993;4:263.
56. Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis. 1993;21(4 suppl l):31-40.
57. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995; 155:1073-1080.
58. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med. 1994;154:1185-1202.
59. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and β-blockers in non-diabetic chronic renal failure. BMJ. 1994;309:833-837.
60. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WM. Effects of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129-138.
61. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992; 41:912-919.
62. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993;153:973-980.
63. Nielsen FS, Rossing P, Gall M-A, Skott P, Smidt UM, Parving H-H. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1994; 43:1108-1113.
64. Lacourciére Y, Nadeau A, Poirier L, Tancréde G. Captopril or conventional therapy in hypertensive type II diabetics: three-year analysis. Hypertension. 1993;21:786-794.
65. Mathiesen ER, Hommel E, Giese J, Parving H-H. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ. 1991;303:81-87.
66. Wiegmann TB, Herron KG, Chenko AM, MacDougall ML, Moore WV. Effect of angiotensin-converting enzyme inhibition on renal function and albuminuria in normotensive type I diabetic patients. Diabetes. 1992;41:62-67.
67. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118: 577-581.
68. Romero R, Salinas I, Lucas A, et al. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors. Diabetes Care. 1993;16:597-600.
69. Vidt DG. The diagnosis of renovascular hypertension: a clinician's viewpoint. Am J Hypertens. 1991;4(Suppl):663-668.
70. Svetkey LP, Saadoon K, Dunnick NR, et al. Similar prevalence of renovascular hypertension in selected blacks and whites. Hypertension. 1991; 17:678-683.
71. Muller FB, Sealey JE, Case DB, et al. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med. 1986;80:633-644.
72. Mann SJ, Pickering TG. Detection of renovascular hypertension: state of the art, 1992. Ann Intern Med. 1992;117:845-853.
73. Nally JV Jr, Olin JW, Lammert GK. Advances in noninvasive screening for renovascular disease. Cleve Clin J Med. 1994;61:328-336.
74. Black HR, Bourgoignie JJ, Pickering T, et al. Report of the working party group for patient selection and preparation. Am J Hypertens. 1991; 4(suppl):745-746.
75. Blaufox MD, Dubovsky EV, Hilson AJW, Taylor A Jr, de Zeeuw R. Report of the working party group on determining the radionuclide of choice. Am J Hypertens. 1991;4(suppl):747-748.
76. 3) for detecting renal artery stenosis. Am J Hypertens. 1991;4(suppl):737-740.
77. Burns PN. The physical principles of Doppler and spectral analysis. J Clin Ultrasound. 1987;15: 567-590.
78. Taylor DC, Kettler MD, Moneta GL, et al. Duplex ultrasound scanning in the diagnosis of renal artery stenosis: a prospective evaluation. J Vase Surg. 1988;7:363-369.
79. Hansen KJ, Tribble RW, Reavis SW, et al. Renal duplex sonography: evaluation of clinical utility. J Vase Surg. 1990;12:227-236.
80. Kim D, Edelman RR, Kent KC, Porter DH, Skillman JJ. Abdominal aorta and renal artery stenosis: evaluation with MR angiography. Radiology. 1990;174:727-731.
81. Debatin JF, Spritzer CE, Grist TM, et al. Imaging of the renal arteries: value of MR angiography. AJP Am J Roentgenol. 1991;157:981-990.
82. Kent KC, Edelman RR, Kim D, Steinman TI, Porter DH, Skillman JJ. Magnetic resonance imaging: a reliable test for the evaluation of proximal atherosclerotic renal arterial stenosis. J Vasc Surg. 1991;13:311-318.
83. Sondergaard L, Sto̊hlberg F, Thomsen C, Stensgaard A, Lindvig K, Henriksen O. Accuracy and precision of MR velocity mapping in measurement of stenotic cross-sectional area, flow rate, and pressure gradient. J Magn Reson Imaging. 1993;3:433-437.
84. Rubin GD, Walker PJ, Dake MD, et al. Three-dimensional spiral computed tomographic angiography: an alternative imaging modality for the abdominal aorta and its branches. J Vase Surg. 1993;18:656-665.
85. Tegtmeyer CJ, Hartwell GD, Selby JB, Robertson R Jr, Kron IL, Tribble CG. Results and complications of angioplasty in aortoiliac disease. Circulation. 1991;83(suppl l):53-60.
86. Puijlaert CBAJ, Boomsma JHB, Ruijs JHJ, et al. Transluminal renal artery dilatation in hypertension: technique, results, and complications in 60 cases. Urol Radiol. 1981;2:201-210.
87. Sos TA, Pickering TG, Sniderman K, et al. Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. N Engl J Med. 1983;309: 274-279.
88. Novick AC. Management of renovascular disease: a surgical perspective. Circulation. 1991; 83(suppl l):167-171.
89. Sos TA. Angioplasty for the treatment of azotemia and renovascular hypertension in atherosclerotic renal artery disease. Circulation. 1991; 83(suppl l):162-166.
90. Schreiber MJ, Pohl MA, Novick AC. The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am. 1984;11:383-392.
91. Tollefson DFJ, Ernst CB. Natural history of atherosclerotic renal artery stenosis associated with aortic disease. J Vase Surg. 1991;14:327-331.
92. Scoble JE, Maher ER, Hamilton G, Dick R, Sweny P, Moorhead JF. Atherosclerotic renovascular disease causing renal impairment - a case for treatment. Clin Nephrol. 1989;31:119-122.
93. Appel RG, Bleyer AJ, Reavis S, Hansen KJ. Renovascular disease in older patients beginning renal replacement therapy. Kidney Int. 1995;48:171-176.
94. Pohl MA, Horner C, Goormastic M, Movick A. Does renal revascularization (RR) preserve renal function in patients with atherosclerotic renal artery stenosis (ARAS)? an ongoing prospective study. J Am Soc Nephrol. 1991;2:242. Abstract.
95. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med. 1993;118:712-719.
96. Palmaz JC, Kopp DT, Hayashi H, et al. Normal and stenotic renal arteries: experimental balloon-expandable intraluminal stenting. Radiology. 1987; 164:705-708.
97. Bacharach JM, Childs MB, Olin JW. Preliminary patency experience with renal artery stents for atherosclerotic renal artery stenosis. In: Parmley WW, ed. Abstracts of the Original Contributions Presented at the 43rd Annual Scientific Sessions of the American College of Cardiology; March 13-17, 1994; Atlanta, Ga. New York, NY: Elsevier Science Publishers; 1994:474.
98. Olin JW, Graor RA, Bacharach JM. Renal artery stenting for control of congestive heart failure. In: Parmley WW, ed. Abstracts of the Original Contributions Presented at the 43rd Annual Scientific Sessions of the American College of Cardiology; March 13-17, 1994; Atlanta, Ga. New York, NY: Elsevier Science Publishers; 1994:96.